linjc16/ctgov huggingface dataset:
The Effect of Spinal Flexion in the Lateral Decubitus Position on the Unilaterality During Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
For unilateral spinal block, spinal local anesthetics should take effect on the spinal nerves of one side. With full flexion of the spine, the cauda equina becomes tightened and hangs in the middle of the subarachnoid space. This study was performed to assess if flexion of the vertebral column facilitates unilateral spinal anesthesia.

Conditions
-----------------
Spinal Anesthesia

Intervention / Treatment
-----------------
* Other: lateral decubitus position with full spinal flexion
* Other: lateral decubitus position without spinal flexion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status Ⅰ-Ⅱ, scheduled for elective knee arthroscopy under spinal anesthesia Exclusion Criteria: Hemodynamically unstable patients Lumbar disease patients with back pain

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.|
|Other: lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time for the complete regression of pinprick spinal analgesia on the nondependent legs |  | Sensory and motor blockade were evaluated within 3 hour of intrathecal injection |
Cardiovascular Risk Factors, Maximal Oxygen Uptake and Sedentariness: an Observational Study

Study Overview
=================
Brief Summary
-----------------
This is a substudy of the Generation-100 study (NCT01666340). The aim of this study is to find critical values for (1) maximal oxygen uptake and (2) sedentary behavior, below which cardiovascular risk parameter clustering is apparent in an elderly Norwegian population.

Official Title
-----------------
Correlation Between Cardiovascular Risk Factors, Sedentary Behaviors and Maximal Oxygen Uptake in an Elderly Norwegian Population

Conditions
-----------------
Aging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ability to walk at least 1km, born in 1938,1939,1940,1941 or 1942 Sufficiently good health to be able to take part in the study, as determined by the researchers Exclusion Criteria: Illness or disability that precludes exercise or hinders completion of the study Uncontrolled hypertension Symptomatic valve disease, hyper tropic cardio-myopathy or unstable angina Active cancer Test results indicating that study participation is unsafe Inclusion in other studies conflicting with participation in this one

Ages Eligible for Study
-----------------
Minimum Age: 70 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Norwegian Elderly Population<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDL blood correlation to maximal oxygen uptake | Maximal oxygen uptake test on the bike or treadmill | baseline | 
| LDL blood correlation to maximal oxygen uptake |  | baseline | 
| C-reactive protein (CRP) correlation to maximal oxygen uptake |  | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sedentariness correlation with maximal oxygen uptake |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physical activity, maximal oxygen uptake
Impact of Body Mass Index on Serum Maternal and Fetal Magnesium Level

Study Overview
=================
Brief Summary
-----------------
Magnesium sulphate is an inorganic salt with multiple therapeutic applications in medicine it has been widely utilized and studied on a diverse set of conditions such as asthma, cardiac arrhythmia and stroke. In pregnant women ,MgSo4 has been used in many cases such as for seizures prophylaxis in preeclampsia, tocolysis in preterm labour and for fetal neuroprotection in immenint preterm delivery.MgSo4 has been used as the standard drug for tocolysis in preterm labour and other drugs have been compared to it.

Official Title
-----------------
Impact of Body Mass Index on Serum Maternal and Fetal Magnesium Level in Pregnant Recipients of Magnesium Sulphate

Conditions
-----------------
Pre-Eclampsia

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: pregnant women 34 weeks or less admitted to Women's Health Hospital with a diagnosis of : sever preeclampsia. It is defined as 1- blood pressure 160/110 mmHg or more 2- proteinurea (+3 or more by dipstick) 3-HELLP syndrome threatened preterm labour that will receive Magnesium Sulphate either for tocolysis or neuroprotection. Exclusion criteria: - women with more than 34 weeks gestation and with any contraindication for Magnesium Sulphate intake like severe renal impairment or myasthenia gravis.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study | Drug: Magnesium Sulfate<br>* 4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the percentage of women reaching the Mg therapeutic level. | the Mg therapeutic level of 4,8 mg/dl. | 24 hours |
A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.

Official Title
-----------------
A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness

Conditions
-----------------
Transient Insomnia

Intervention / Treatment
-----------------
* Drug: Gabapentin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 18 years or older with symptoms of sleeplessness Provided informed consent Exclusion Criteria: Contraindications to use of gabapentin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: Gabapentin<br>* Gabapentin 50 mg oral capsule 30 minutes before bedtime<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects who selected or purchased gabapentin for use (patients had symptoms consistent with indication and no contraindications) |  | Throughout Day 90 | 
| Subject compliance with directions for use (number of capsules per dose and the number of doses per day) |  | Throughout Day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  | Duration of study |
Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections

Study Overview
=================
Brief Summary
-----------------
Before Daptomycin (Cubicin ®) approved by the U.S. FDA in 2003, There were large-scale clinical trials conducted that included more than 1,000 subjects and than Daptomycin got complicated skin and soft tissue infections (CSSSI) indication. After 2004, Daptomycin got new indications about bacteremia and endocarditis due to success outcomes in the clinical trial which included infected in blood flow and endocardial infected patients. All subjects in Daptomycin clinical trials are European and American race. It is necessary that collecting safety and efficacy data of Daptomycin in Taiwan race. I will intent to evaluate the safety and efficacy of Daptomycin which were used in patients with serious gram-positive infections retrospectively. And the outcome could be a reference for Daptomycin future using.

Conditions
-----------------
Bacteremia, Endocarditis, Serious Gram-positive Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients who were prescribed daptomycin from 1st January 2009 to 31st December 2010 for gram positive infections as deemed necessary by his/her treating physician. And patients received Daptomycin therapy for at least 3 days. Exclusion Criteria: Patients received Daptomycin therapy for over 3 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy

Study Overview
=================
Brief Summary
-----------------
This study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which has failed to shrink or has returned after previous treatment with chemotherapy. The purpose of this study is to find out whether patients with these types of cancer will have their tumor shrunk after treatment with a drug called Noscapine. The second purpose is to see what are the side effects of this drug. This drug is being used as an over-the-counter cough suppressor in Europe and Japan, but has also shown to be effective against cancer.

Official Title
-----------------
Phase I/II Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy

Conditions
-----------------
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Intervention / Treatment
-----------------
* Drug: Noscapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with low grade NHL (follicular lymphoma, small cell lymphocytic lymphoma, marginal cell lymphoma, monocytoid B-cell lymphoma, MALT lymphoma, plasmacytoid lymphocytic lymphoma) or chronic lymphocytic leukemia who have demonstrated chemotherapy resistance (have not achieved CR,CRu, PR)or who have relapsed at any time following a response (CR, CRu, PR) after at least one therapy regimen, including chemotherapy, Rituximab, or high dose chemotherapy with stem cell rescue. Karnofsky performance status 60 % or greater. Creatinine less or equal to 2.0 mg/dl, bilirubin less or equal to 2.0 mg/dl, SGPT/SGOT less or equal to 4 x upper normal range Exclusion Criteria: Patients with unconfirmed complete response(CRu)after last treatment and who currently remain in CRu. Pregnant or lactating women. Disease-specific treatment less than 1 month prior to starting this study. CNS disease. HIV-positive patients. Other cancer, except basal cell or squamous cell cancer of the skin or carcinoma in-situ of cervix.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Noscapine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

Official Title
-----------------
Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Conditions
-----------------
Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Drug: Budesonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of respiratory distress syndrome Exclusion Criteria: pneumothorax surgical disease major congenical defects

Ages Eligible for Study
-----------------
Maximum Age: 12 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Cursurf<br>The baby with respiratory distress syndrome was given Cursurf through intubation. | |
| Experimental: Cursurf and Budesonide<br>The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation. | Drug: Budesonide<br>* Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation<br>* Other names: Pumicort;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| need of pulmonary surfactant | The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of bronchopulmonary dysplasia | the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia. | gestional age 36 weeks or later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infant, respiratory distress syndrome
Impact of 3-year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study

Study Overview
=================
Brief Summary
-----------------
To evaluate the effect of a 3-year diet- and exercise lifestyle intervention, based on general public health recommendations, on glucose tolerance, insulin resistance and metabolic cardiovascular risk factors in Dutch subjects with impaired glucose tolerance (IGT).

Detailed Description
-----------------
Objective To evaluate the effect of a 3-year diet- and exercise lifestyle intervention, based on general public health recommendations, on glucose tolerance, insulin resistance and metabolic cardiovascular risk factors in Dutch subjects with impaired glucose tolerance (IGT). Research design and methods 147 IGT subjects (75 male, 72 female) were randomized to the intervention group (INT) or control group (CON). 106 subjects (52 INT, 54 CON) completed 3 years of intervention. Annually, glucose, insulin and FFA concentrations were determined during fasting and after an oral glucose tolerance test, in addition to measurements of body weight, serum lipids, blood pressure and maximal aerobic capacity.

Official Title
-----------------
Impact of 3-year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study

Conditions
-----------------
Impaired Glucose Tolerance, Type 2 Diabetes

Intervention / Treatment
-----------------
* Behavioral: diet- and exercise intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: caucasion,age 40-70, mean 2hr glucose 7.8-12.5 mmol/l, mean fasting blood glucose below 7.8 Exclusion Criteria: known type 2 diabetes, mean 2hr glucose >12.5 mmol/l, mean fasting blood glucose > 7.8 mmol/l, chronic illness that makes 5-year survival improbable, interferes with glucose tolerance or makes participation in a lifestyle intervention impossible, medication known to interfere with glucose tolerance, participation in a vigorous exercise and/or diet program

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: diet- and exercise intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2-hour glucose levels |  |  | 
| insulin resistance |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adherence |  |  | 
| type 2 diabetes |  |  | 
| dietary intake change |  |  | 
| exercise change |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
impaired glucose tolerance, type 2 diabetes
Atrio-Ventricular (AV) Delay Optimization Using Echocardiography Versus the SonR Signal

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate an external device (SonR sensor) that is capable of detecting sounds created by the heart (SonR signal). Based on the sounds created by the heart and recorded by the SonR sensor, optimal timing settings for the cardiac resynchronization therapy defibrillator (CRT-D) device may be determined. The investigators will then compare the timing settings suggested by SonR to the settings suggested from the echocardiogram. The objective of this study is to determine if differences exist between these different methods of timing the contractions of the top and bottom chambers of the heart and if the SonR signal is able to produce results similar to those of an echocardiogram.

Official Title
-----------------
Atrio-Ventricular Delay Optimization in Patients Implanted With a Cardiac Resynchronization Device Using Echocardiography Versus the SonR Signal: A Pilot Study

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Other: Echocardiogram/SonR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Implanted with any current Food and Drug Administration (FDA) approved CRT- D device and leads for 30 days or patients indicated for AV optimization ≥18 years of age Ability and willingness to provide written informed consent and HIPAA authorization Exclusion Criteria: Chronic Atrial Fibrillation Heart Failure decompensation event within two weeks of enrollment Hypertrophic Obstructive Cardiomyopathy Patient currently enrolled in another ongoing clinical trial Pregnancy Less than 18 years of age Inability or unwillingness to provide written informed consent and HIPAA authorization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: All Patients<br>All patients will have an echocardiogram and SonR sensor readings completed. | Other: Echocardiogram/SonR<br>* All patients will have an echocardiograph and SonR sensor readings<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optimal blood flow method | To determine the best method of timing the contractions of the top and bottom chambers of the heart by using echocardiography versus using signals of the external SonR sensor. | 3 months |